Intoxicating Cannabinoids: What you need to know

Introduction

Intoxicating cannabinoids have become one of the most widely discussed topics in the cannabis and hemp industry, driven largely by the new U.S. hemp rule that reshapes how these compounds are defined, regulated, and marketed. This updated rule, which redefines hemp and establishes a 0.4 mg total THC limit, is forcing brands to rethink their production methods, labeling practices, and overall compliance strategies. It also bans products that contain hemp-derived cannabinoids synthesized or manufactured outside the plant’s natural pathways, as well as all natural and converted THC forms in consumable formats such as gummies, beverages, vapes, and topical creams.

It is important to note that most THC-derived cannabinoids are intoxicating, and this makes consumer education more important than ever. As the industry awaits a finalized list of compounds that will count toward total THC, consumers need clear guidance on what these cannabinoids are, how they differ, and which forms may pose higher risks.

What Are Intoxicating Cannabinoids?

Intoxicating cannabinoids are compounds that can alter perception, mood, coordination, and overall mental state, and they achieve these effects through strong activity at CB1 receptors in the brain. Some of these cannabinoids occur naturally in the cannabis and hemp plant, although many are present only in trace amounts, while some are created via controlled conversion of non-intoxicating cannabinoids like CBD. 

A key distinction between intoxicating and non-intoxicating cannabinoids lies in how they interact with the endocannabinoid system. Compounds such as CBD, CBDA, and CBG have minimal impact on CB1 receptors and therefore do not create a high. In contrast, intoxicating cannabinoids like Delta 9 THC, Delta 8 THC, THCP, and HHC show a much stronger affinity for CB1, which is why their effects are more noticeable. This differentiation is widely recognized in cannabinoid science and is supported by both laboratory research and real-world consumer experiences.

List of Intoxicating Cannabinoids Found in the Hemp Market

Naturally Occurring Intoxicating Cannabinoids

Naturally occurring intoxicating cannabinoids are compounds produced directly by the cannabis and hemp plant through its inherent biochemical pathways. These molecules arise through natural enzymatic processes and oxidative transformations that take place during the plant’s growth and maturation. Although many of these cannabinoids appear only in trace concentrations, their structural similarity to THC allows them to interact with CB1 receptors in the brain, resulting in measurable psychoactive or psychotropic effects. Because they originate from natural plant biosynthesis, these cannabinoids are considered part of the plant’s native chemical profile and are frequently referenced in scientific literature examining cannabis pharmacology and cannabinoid diversity.

Some of the most common examples are discussed below;

Δ⁹-THC (Delta 9 Tetrahydrocannabinol)

Δ⁹-THC is the primary intoxicating cannabinoid found in the cannabis plant and remains the most extensively studied compound in cannabinoid science. It was first isolated and identified in 1964 by Professor Raphael Mechoulam and Dr. Yechiel Gaoni at the Weizmann Institute of Science in Israel. Their work established the chemical structure of Δ⁹-THC and marked a major turning point in modern cannabis research, as it provided the scientific foundation for understanding why cannabis produces psychoactive effects.

In the plant, Δ⁹-THC forms through enzymatic conversion of cannabigerolic acid (CBGA) into tetrahydrocannabinolic acid (THCA), which then decarboxylates into Δ⁹-THC when exposed to heat or prolonged light. 

Structurally, Δ⁹-THC is a phytocannabinoid featuring a tricyclic ring system and a pentyl side chain that significantly contributes to its binding strength. Research indicates that a minimum of three carbon atoms in the side chain is required to interact effectively with CB receptors, and increasing the number of carbons generally enhances binding affinity. The “delta-9” designation refers to the position of a double bond on the ninth carbon of the cyclohexene ring, a detail that influences how precisely the molecule interacts with CB1 receptors in the brain.

Its strong affinity for CB1 receptors is what makes Δ⁹-THC intoxicating. When it binds to these receptors, it modulates neurotransmitter release, alters reward and perception pathways, and produces changes in mood, coordination, memory, and sensory processing. Δ⁹-THC is also highly lipophilic, allowing it to store in fatty tissues and remain in the body longer than its immediate effects suggest.

Because Δ⁹-THC has a well-characterized structure and pharmacological profile, it continues to serve as the benchmark for evaluating the potency and effect profiles of other intoxicating cannabinoids. Many natural, semi-synthetic, and synthetic THC analogs reference Δ⁹-THC as the standard for comparison in cannabinoid science, regulatory frameworks, and product development.

Δ⁸-THC (Delta 8 Tetrahydrocannabinol)

Δ⁸-THC is a naturally occurring cannabinoid closely related to Δ⁹-THC, with both compounds sharing the same molecular formula but differing in the position of a double bond. In Δ⁸-THC, the double bond is located on the eighth carbon of the cyclohexene ring, which slightly alters its chemical stability and psychoactive potency compared with Δ⁹-THC. This minor structural difference makes Δ⁸-THC less potent than Δ⁹-THC, but it still binds to CB1 receptors in the brain to produce intoxicating effects.

Δ⁸-THC was first identified in 1941 by Dr. Roger Adams, an American chemist, who isolated it from cannabis resin and elucidated its chemical structure. While it occurs naturally in cannabis and hemp, it is found only in trace amounts. Because of this scarcity, most Δ⁸-THC products on the market today are produced through a controlled isomerization process that converts CBD or Δ⁹-THC into Δ⁸-THC using established chemical pathways. This semi-synthetic approach allows for consistent potency and purity in commercial products.

Like Δ⁹-THC, Δ⁸-THC has a pentyl side chain, which is essential for CB receptor interaction. The pentyl chain in Δ⁸-THC ensures it maintains the ability to interact with CB1 receptors, producing psychoactive and psychotropic effects, though generally milder and often described as less anxiety-inducing than Δ⁹-THC.

Δ⁸-THC has garnered attention in both research and the hemp marketplace because it offers an intoxicating experience with slightly lower potency and a different effect profile. Its structural similarity to Δ⁹-THC makes it a key reference point for understanding cannabinoid isomerization and the diverse range of THC-derived intoxicating cannabinoids.

Δ⁹-Tetrahydrocannabutol (Δ⁹-THCB)

Δ⁹-Tetrahydrocannabutol (Δ⁹-THCB) is a naturally occurring intoxicating cannabinoid first identified by a team of Brazilian researchers during a comprehensive investigation of minor cannabinoids in Cannabis sativa. THCB is structurally similar to Δ⁹-THC, but with one key difference: it carries a butyl (four-carbon) side chain instead of the typical pentyl (five-carbon) chain found in Δ⁹-THC.

This structural shift is significant because the length of the alkyl side chain directly influences how well a cannabinoid binds to the CB1 receptor. Although it was hypothesized that the higher the chain length the greater the binding affinity, THCB showed an in vitro CB1 affinity 3-fold higher than THC. 

Early pharmacological data from the initial discovery study revealed that THCB exhibits high affinity for both CB1 and CB2 receptors, suggesting that it can produce intoxicating effects. Human data is however still limited.

THCB occurs naturally but only in trace amounts, which makes commercial quantities dependent on advanced extraction or semi-synthetic processes. 

THCH (Tetrahydrocannabihexol)

THCH, or tetrahydrocannabihexol, is a naturally occurring intoxicating cannabinoid that is structurally similar to Δ⁹-THC but distinguished by its hexyl (six-carbon) side chain. This longer side chain increases its binding affinity to CB1 receptors in the brain, which may result in stronger psychoactive effects compared with cannabinoids that have shorter side chains, such as Δ⁹-THC (pentyl) or Δ⁸-THC (pentyl). 

THCH was first reported in 2020 during analytical studies of minor cannabinoids in cannabis, highlighting the expanding diversity of THC analogs. 

It was reported alongside with CBDH, a corresponding heptyl (7 carbon) derivative of CBD. Since then there has been little to on information about the compound. Like other THC derivatives, it binds to CB1 receptors to produce intoxicating and psychotropic effects, potentially more potent than Δ⁹-THC due to its structural modifications.

Although it occurs naturally in trace amounts, most commercial THCH products are derived through selective extraction or semi-synthetic concentration methods to achieve usable levels for research or consumer products. 

THCP (Δ⁹-Tetrahydrocannabiphorol)

THCP, or Δ⁹-tetrahydrocannabiphorol, is a naturally occurring intoxicating cannabinoid first discovered in 2019 by Italian researchers led by Dr. Cinzia Citti during a detailed analysis of minor cannabinoids in Cannabis sativa. Structurally, THCP mirrors Δ⁹-THC but features a heptyl (seven-carbon) alkyl side chain instead of THC’s pentyl (five-carbon) chain.

This structural extension is extremely significant. THCP’s seven-carbon chain allows it to interact more deeply with the CB1 receptor’s binding pocket, which enhances its pharmacological strength.

In the original discovery study, THCP displayed 33 times greater affinity for the CB1 receptor than Δ⁹-THC in vitro, making it one of the most potent naturally occurring cannabinoids ever identified. It was also reported to be 63 times more active than THCV, 13 times more active than THCB and 5-10 times more active against CB2 receptors than THC.  

Although THCP is a natural phytocannabinoid, it occurs in extremely low concentrations in the plant. As a result, most commercial THCP found in consumer products is produced through advanced extraction, concentration, or controlled conversion processes. 

THCJD (Tetrahydrocannabioctyl / Octyl-Chain THC Analog)

THCJD is an intoxicating cannabinoid known for its unusually long octyl (eight-carbon) side chain, which sets it apart from Δ⁹-THC (five carbons) and THCP (seven carbons). 

Although many industry sources claim that THCJD was first identified in 2020 during analyses of cannabis extracts that revealed several long-chain THC analogs, there is limited verifiable information about the specific scientific team or publication behind this discovery. What is clear from available analytical reports is that THCJD appears to occur naturally in the plant, but only in trace concentrations, far lower than those of major cannabinoids such as Δ⁹-THC or CBD.

Some sources suggest that THCJD may not be a newly discovered cannabinoid at all. Instead, it may be another name for an isomer first identified as early as 1941, known in the literature as THC-Octyl, Δ⁸-THC-C8, or referenced in synthetic cannabinoid research as JWH-138. In the research, they also mentioned the possibility of a nonyl side chained cannabinoid with over 70-fold potency than THC. 

If these designations indeed refer to the same compound, it raises an important question: why has the modern cannabis industry adopted the new name “THCJD”? Without clear scientific documentation connecting the historical compound to the contemporary terminology, any explanation remains speculative.

Importantly, THCJD remains a highly debated cannabinoid within both scientific and regulatory circles. While laboratory observations and some analytical reports suggest potent CB1 receptor activity, the peer-reviewed literature is limited, and no definitive pharmacological potency data have been published to confirm its real-world effects. This lack of validated studies has led to ongoing discussion about how potent THCJD truly is, whether it behaves similarly to other long-chain THC analogs, and how it should be classified under evolving hemp regulations.

Due to its scarcity in the plant, THCJD found in consumer products is typically obtained through semi-synthetic conversion methods. 

THCV (Tetrahydrocannabivarin)

THCV, or tetrahydrocannabivarin, is a naturally occurring cannabinoid closely related to Δ⁹-THC, but distinguished by its propyl (three-carbon) side chain instead of the pentyl (five-carbon) chain in THC. This shorter side chain reduces its binding affinity for CB1 receptors, which means THCV generally produces minimal intoxicating effects at typical consumption levels.

While its time of discovery is quite unclear, THCV was reported in a 1942 research led by Roger Adams. It is highly abundant in African and Asian cannabis varieties. Structurally, like other THC analogs, THCV has a tricyclic ring system that allows it to interact with CB1 and CB2 receptors, but its three-carbon side chain limits the strength of this interaction. At low doses (typically below 10 mg), THCV is largely non-intoxicating, often producing mild stimulatory or appetite-suppressing effects instead. Higher doses, however, generally above 200 mg, have been reported in studies and anecdotal reports to produce clear intoxicating effects, though still milder and shorter-lasting compared with Δ⁹-THC.

THCV occurs naturally in cannabis, often in trace amounts, particularly in landrace African sativas. Its pharmacological profile is unique: at low doses, it can act as a CB1 receptor antagonist, reducing psychoactivity, whereas at higher doses, it switches to a partial CB1 agonist, producing mild intoxication.

An alternative isomer, Δ⁸-THCV, is known as a synthetic compound with the code number O-4395, but it is not known to have been isolated from cannabis plant material. 

Semi-Synthetic / Conversion-Derived Intoxicating Cannabinoids

Semi-synthetic or conversion-derived cannabinoids are compounds produced by chemically modifying naturally occurring cannabinoids extracted from hemp or cannabis, most commonly CBD. These processes follow well-established chemical pathways to create cannabinoids that either do not occur in significant natural quantities or are structurally altered to enhance potency, stability, or bioavailability.

Examples include Δ⁸-THC, THCP, and certain rare THC analogs. While these cannabinoids can produce intoxicating effects similar to Δ⁹-THC, their potency, receptor affinity, and pharmacological profiles can differ significantly depending on the conversion process and the resulting molecular structure.

From a regulatory and safety perspective, semi-synthetic cannabinoids require rigorous testing and quality control, as improper conversion can yield contaminants or unintended byproducts. Some of the cannabinoids that fall under this category include but are not limited to the following: 

• HHC – Hexahydrocannabinol
• HHC-O – Hexahydrocannabinol Acetate
• THC-O – THC-O-Acetate (Tetrahydrocannabinol Acetate)
• HC-P-O – Tetrahydrocannabiphorol Acetate
• Δ¹⁰-THC – Delta-10-Tetrahydrocannabinol
• Δ⁶a,10a-THC – Delta-6a,10a-Tetrahydrocannabinol
• HHCP – Hexahydrocannabiphorol
• HHCH– Hexahydrocannabihexol
• 11-Hydroxy-THC (metabolite but crucial for effects)
• Variants from isomerization (Δ7-THC, Δ11-THC, etc.)

Safety Considerations: What Consumers Should Know

As the market for intoxicating cannabinoids continues to expand, consumer safety must remain a top priority. One of the most important considerations is lab testing. Reputable products should undergo rigorous analysis to ensure they are free from residual solvents, heavy metals, pesticides, and microbial contaminants. Independent third-party testing not only confirms product safety but also verifies potency and cannabinoid content, helping consumers make informed choices.

Potency and purity can vary widely across the market, especially for semi-synthetic or conversion-derived cannabinoids like Δ⁸-THC, THCP, and HHC. Inconsistent dosing may lead to unpredictable effects, making it essential to start with low doses and gradually increase while monitoring individual tolerance.

Common side effects of intoxicating cannabinoids include dry mouth, dizziness, fatigue, and altered perception or coordination. Overconsumption can exacerbate these effects and may temporarily impact cognitive or motor function. Consumers should also be aware of tolerance buildup, as repeated use can reduce sensitivity to psychoactive effects over time, potentially leading to higher consumption and increased risk of adverse reactions.

References:

1. Adams, R., Loewe, S., Smith, C.M. and McPhee, W.D. (1942). Tetrahydrocannabinol Homologs and Analogs with Marihuana Activity. XIII1. Journal of the American Chemical Society, 64(3), pp.694–697. https://doi.org/10.1021/ja01255a061. 
2. Caprari, C., Ferri, E., Schmid, M.G., Del Mercato, L.L., Citti, C. and Cannazza, G. (2024). Δ9-Tetrahydrocannabiphorol: Identification and quantification in recreational products. Forensic Chemistry, [online] 40, p.100595. https://doi.org/10.1016/j.forc.2024.100595. 
3. Citti, C., Linciano, P., Russo, F., Luongo, L., Iannotta, M., Maione, S., Laganà, A., Capriotti, A.L., Forni, F., Vandelli, M.A., Gigli, G. and Cannazza, G. (2019a). A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol. Scientific Reports, 9(1). https://doi.org/10.1038/s41598-019-56785-1.
4. Clarkhill.com. (2025). Hemp Industry Alert: Federal Ban on Hemp-Derived THC Products – Immediate Action Required | News & Events | Clark Hill PLC. [online] Available at: www.clarkhill.com/news-events/news/hemp-industry-alert-federal-ban-on-hemp-derived-thc-products-immediate-action-required/. 
5. Hakan Kayir, Kouroukis, L., Aziz, I. and Khokhar, J.Y. (2025). Tetrahydrocannabivarin (THCV) Dose Dependently Blocks or Substitutes for Tetrahydrocannabinol (THC) in a Drug Discrimination Task in Rats. Biomolecules, [online] 15(9), pp.1329–1329. https://doi.org/10.3390/biom15091329. 
6. Linciano, P., Citti, C., Russo, F., Tolomeo, F., Laganà, A., Capriotti, A.L., Luongo, L., Iannotta, M., Belardo, C., Maione, S., Forni, F., Vandelli, M.A., Gigli, G. and Cannazza, G. (2020). Identification of a new cannabidiol n-hexyl homolog in a medicinal cannabis variety with an antinociceptive activity in mice: cannabidihexol. Scientific Reports, [online] 10(1), p.22019. https://doi.org/10.1038/s41598-020-79042-2. 
7. Maccarrone, M. (2022). Tribute to Professor Raphael Mechoulam, The Founder of Cannabinoid and Endocannabinoid Research. Molecules, [online] 27(1), p.323. https://doi.org/10.3390/molecules27010323.
8. Martin, B.R., Jefferson, R., Winckler, R., Wiley, J.L., Huffman, J.W., Crocker, P.J., Saha, B. and Razdan, R.K. (1999). Manipulation of the Tetrahydrocannabinol Side Chain Delineates Agonists, Partial Agonists, and Antagonists. Journal of Pharmacology and Experimental Therapeutics, 290(3), pp.1065–1079. https://doi.org/10.1016/s0022-3565(24)35007-4.
9. Siracusa, L., Ruberto, G. and Cristino, L. (2023). Recent Research on Cannabis sativa L.: Phytochemistry, New Matrices, Cultivation Techniques, and Recent Updates on Its Brain-Related Effects (2018–2023). Molecules, [online] 28(8), p.3387. https://doi.org/10.3390/molecules28083387.